Senior Correspondent, London
Ben's Feed
Aug 11, 2014

Sanofi bets on inhaled insulin with up to $925 million MannKind deal

PARIS/LONDON (Reuters) – French drugmaker Sanofi (SASY.PA: Quote, Profile, Research) is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp (MNKD.O: Quote, Profile, Research) worth up to $925 million (551.02 million British pound).

Inhalation promises people with diabetes much greater convenience than routine injections but it remains unclear how widely it will be adopted, given concerns about the potential risks associated with breathing powdered insulin into the lungs.

Aug 11, 2014

eb UPDATE 1-Sanofi bets on inhaled insulin with up to $925 mln MannKind deal

PARIS/LONDON, Aug 11 (Reuters) – French drugmaker Sanofi
is betting on inhaled insulin as an alternative option
to daily injections for diabetics by signing a worldwide
licensing agreement with MannKind Corp worth up to $925
million.

Inhalation promises people with diabetes much greater
convenience than routine injections but it remains unclear how
widely it will be adopted, given concerns about the potential
risks associated with breathing powdered insulin into the lungs.

Aug 10, 2014

Clinical trial to start soon on GSK Ebola vaccine

LONDON, Aug 10 (Reuters) – A clinical trial of an
experimental vaccine against the deadly Ebola virus is set to
start shortly, according to British drugmaker GlaxoSmithKline
, which is co-developing the product with U.S.
scientists.

The world’s worst outbreak of Ebola has killed nearly 1,000
people in West Africa and the disease could continue spreading
for months, increasing pressure on researchers to accelerate
their work on new medical interventions.

Aug 5, 2014
Aug 5, 2014
Aug 5, 2014

Hopes build for new Novartis heart failure drug

LONDON (Reuters) – Expectations are building for a new heart failure drug from Novartis viewed as a likely multibillion-dollar seller, with two surveys of cardiologists published on Tuesday highlighting its potential.

A large clinical trial with LCZ696 was stopped early in March because the benefit to patients was overwhelmingly positive. Just how good the drug was will be disclosed at a medical meeting in Spain at the end of this month.

Aug 4, 2014

GSK gets a lift as Express Scripts reinstates lung drug Advair

LONDON (Reuters) – GlaxoSmithKline (GSK) received a boost on Monday from a decision by Express Scripts, the largest U.S. pharmacy benefit manager, to reinstate its top-selling lung drug Advair as an approved drug in 2015.

The British drugmaker’s business has suffered since January after Advair was dropped from various formulary lists, including that of Express Scripts, adding to pressure on an inhaled medicine that is also facing growing price competition from rival products.

Aug 1, 2014
Aug 1, 2014

Smith & Nephew offers low-cost hip, knee service in U.S.

LONDON, Aug 1 (Reuters) – Smith & Nephew, Europe’s
largest maker of artificial joints, is to offer U.S. customers a
new “no frills” service that will slash the cost of buying its
replacement hips and knees.

Chief Executive Olivier Bohuon said the so-called Syncera
service, designed to strengthen S&N’s position in a highly
competitive market, would appeal to between 5 and 10 percent of
U.S. hospitals that cannot afford its full-service offering.

Jul 31, 2014

AstraZeneca steps up push into cancer immunotherapy

LONDON (Reuters) – AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types.

The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body’s immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben